(0.30%) 5 115.24 points
(0.31%) 38 359 points
(0.31%) 15 977 points
(-0.93%) $83.07
(5.56%) $2.03
(0.35%) $2 355.40
(0.44%) $27.66
(4.03%) $959.25
(-0.24%) $0.932
(-0.43%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
@ CNY10.28
発行日: 15 2月 2024 @ 05:48
リターン: -0.29%
前回のシグナル: 2月 15 - 03:13
前回のシグナル:
リターン: -0.48 %
Live Chart Being Loaded With Signals
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...
Stats | |
---|---|
本日の出来高 | 6.37M |
平均出来高 | 1.46M |
時価総額 | 989.87M |
EPS | CNY0 ( 2024-03-11 ) |
次の収益日 | ( CNY0 ) 2024-05-13 |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -10.57 |
ATR14 | CNY0.215 (2.10%) |
ボリューム 相関
Gracell Biotechnologies 相関
10 最も負の相関 | |
---|---|
ITMR | -0.929 |
OPNT | -0.929 |
AVEO | -0.925 |
VLYPP | -0.923 |
DVCR | -0.923 |
CIH | -0.918 |
BKCH | -0.916 |
FRGI | -0.915 |
EWEB | -0.907 |
MLCO | -0.901 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Gracell Biotechnologies 相関 - 通貨/商品
Gracell Biotechnologies 財務諸表
Annual | 2022 |
収益: | CNY0 |
総利益: | CNY0 (0.00 %) |
EPS: | CNY-5.65 |
FY | 2022 |
収益: | CNY0 |
総利益: | CNY0 (0.00 %) |
EPS: | CNY-5.65 |
FY | 2021 |
収益: | CNY366 000 |
総利益: | CNY0.00 (0.00 %) |
EPS: | CNY-4.31 |
FY | 2020 |
収益: | CNY0.00 |
総利益: | CNY0.00 (0.00 %) |
EPS: | CNY-13.85 |
Financial Reports:
No articles found.
Gracell Biotechnologies
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。